Compare
Lexicon Pharmaceuticals, Inc. vs Ocular Therapeutix, Inc vs Agios Pharmaceuticals, Inc. vs Nektar Therapeutics
| Latest fiscal year | Lexicon Pharmaceuticals, Inc. LXRX | Ocular Therapeutix, Inc OCUL | Agios Pharmaceuticals, Inc. AGIO | Nektar Therapeutics NKTR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $49.80M | $51.95M | $54.03M | $55.23M |
| Revenue growth (YoY) | +60.2% | -18.5% | +48.0% | -43.9% |
| Gross margin | n/a | 87.3% (computed) | 88.3% (computed) | n/a |
| Operating margin | -98.2% | -519.8% | -873.9% | -253.7% |
| Net margin | -101.1% | -511.9% | -764.0% | -297.1% |
| Net income | -$50.34M | -$265.94M | -$412.78M | -$164.08M |
| EPS (Diluted) | -$0.14 | -$1.42 | -$7.12 | -$9.73 |
| Operating cash flow | -$67.85M | -$204.88M | -$372.98M | -$208.51M |
| Free cash flow | -$67.85M | -$216.89M | -$377.29M | -$208.68M |
| Cash & equivalents | $34.33M | $737.06M | $89.13M | $15.12M |
| Total assets | $184.99M | $808.06M | $1.30B | $280.41M |
| Total liabilities | $77.45M | $153.75M | $104.11M | $190.57M |
| Shareholders' equity | $107.54M | $654.31M | $1.19B | $89.83M |
| Return on year-end equity | -46.8% | -40.6% | -34.6% | -182.6% |
| Shares outstanding | 365.85M | 215.93M | 58.45M | 20.38M |
Revenue, most recent five fiscal years
| Fiscal year | Lexicon Pharmaceuticals, Inc. | Ocular Therapeutix, Inc | Agios Pharmaceuticals, Inc. | Nektar Therapeutics |
|---|---|---|---|---|
| Latest | $49.80M Ended 2025-12-31 | $51.95M Ended 2025-12-31 | $54.03M Ended 2025-12-31 | $55.23M Ended 2025-12-31 |
| 1 year earlier | $31.08M Ended 2024-12-31 | $63.72M Ended 2024-12-31 | $36.50M Ended 2024-12-31 | $98.43M Ended 2024-12-31 |
| 2 years earlier | $1.20M Ended 2023-12-31 | $58.44M Ended 2023-12-31 | $26.82M Ended 2023-12-31 | $90.12M Ended 2023-12-31 |
| 3 years earlier | $139.0K Ended 2022-12-31 | $51.49M Ended 2022-12-31 | $14.24M Ended 2022-12-31 | $92.06M Ended 2022-12-31 |
| 4 years earlier | $298.0K Ended 2021-12-31 | $43.52M Ended 2021-12-31 | $0 Ended 2021-12-31 | $101.91M Ended 2021-12-31 |